الخميس 10 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting | MSD | Completed | Sitagliptin | 4 | MK0431-263 | Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh) |
| A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD) | Roche | Completed | Pegasys | 4 | MV22009 | King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj) |
| A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan | Novartis | Completed | Vildagliptin / Sulphonylurea / Metformin | 4 | CLAF237A-MAX-AE-02 | Soliman Fakeeh Hospital (Jeddah) |
| A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan. | Novartis | Completed | Vildagliptin /Gliclazide / Metformin | 4 | CLAF237A2411 | King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh) |
| UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER) | Novartis | Completed | Ranibizumab | 4 | CRFB0021 | King Khaled Eye Specialist Hospital (Riyadh) |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk | Boehringer Ingelheim | Completed | BI 10773 | 3 | 1245.25 | King Fahad Medical City (Riyadh) |
| Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma | Roche | Completed | Bevacizumab | 3 | MO22923 | King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam) |
| Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS | Eagle Pharmaceuticals | Completed | Dantrolene | 2 | EGL-4104-C-1502 | King Fahad Medical City (Riyadh) |
| An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency | Synageva | Completed | Sebelipase alfa (SBC-102) | 2 | LAL-CL03 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes | Intarcia Therapeutics | Completed | ITCA 650 | 3 | ITCA 650-CLP-105 | King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)_ Imam Abdulrahman Al Faisal Hospital NG (Dammam)_ King Fahad Medical City (Riyadh) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.